Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 7/20 | 0.44 |
| ▸ | PPARD | Q03181 | 7/20 | 0.44 |
| ▸ | PPARA | Q07869 | 7/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | FABP4 | P15090 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15288850 | 1.00 | TSHR (0.55) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL13446629 | 1.00 | TSHR (0.55) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL16506913 | 1.00 | TSHR (0.55) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL25263751 | 1.00 | TSHR (0.55) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL13651619 | 1.00 | TSHR (0.55) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL25408049 | 1.00 | TSHR (0.55) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL13736453 | 1.00 | TSHR (0.55) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL14129678 | 1.00 | TSHR (0.55) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL20626797 | 1.00 | TSHR (0.55) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL13866617 | 1.00 | TSHR (0.55) | TSHRLMNANFKB1PMP22GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230099200-A1 | RADIOLABELED PEPTIDES FOR NON-INVASIVE DIAGNOSIS AND TREATMENT OF CXCR4 EXPRESSING TUMORS | ISTITUTO NAZIONALE TUMORI IRCCS - FONDAZIONE G. PASCALE (IT) | 2023-03-30 | — | — | US | claimed |
| EP-4081263-A1 | RADIOLABELED PEPTIDES FOR NON-INVASIVE DIAGNOSIS AND TREATMENT OF CXCR4 EXPRESSING TUMORS | Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale (IT) | 2022-11-02 | — | — | EP | claimed |
| CN-115703736-B | Multi-target inhibitor targeting HDAC and NAD synthesis and application thereof | 中国海洋大学 | 2025-05-16 | — | — | CN | disclosed |
| CN-119930717-A | 1-Triazole ribose derivative and preparation method and application thereof | 上海泓博智源医药股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20240327418-A1 | MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR | OCEAN UNIVERSITY OF CHINA (CN) | 2024-10-03 | — | — | US | disclosed |
| EP-4093730-B1 | HDAC DEGRADER | UNIV LEICESTER (GB) | 2024-05-08 | — | — | EP | disclosed |
| US-20230120211-A1 | HDAC Degrader | UNIVERSITY OF LEICESTER (GB) | 2023-04-20 | — | — | US | disclosed |
| US-20230099200-A1 | RADIOLABELED PEPTIDES FOR NON-INVASIVE DIAGNOSIS AND TREATMENT OF CXCR4 EXPRESSING TUMORS | ISTITUTO NAZIONALE TUMORI IRCCS - FONDAZIONE G. PASCALE (IT) | 2023-03-30 | — | — | US | disclosed |
| WO-2023011416-A1 | MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR | 中国海洋大学 | 2023-02-09 | — | — | WO | disclosed |
| EP-4093730-A1 | HDAC DEGRADER | University of Leicester (GB) | 2022-11-30 | — | — | EP | disclosed |
| EP-4081263-A1 | RADIOLABELED PEPTIDES FOR NON-INVASIVE DIAGNOSIS AND TREATMENT OF CXCR4 EXPRESSING TUMORS | Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale (IT) | 2022-11-02 | — | — | EP | disclosed |
| WO-2013148189-A1 | PROBE INCORPORATION MEDIATED BY ENZYMES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013052851-A1 | METHODS AND COMPOSITIONS FOR POLYPEPTIDE AND PROTEIN LABELING USING LIPOIC ACID LIGASES SPECIFIC TO RESORUFIN | MASSACHUSETTS INISTITUTE OF TECHNOLOGY (US) | 2013-04-11 | — | — | WO | disclosed |
| WO-2012152807-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | UNIVERSITEIT ANTWERPEN (BE) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012152807-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | UNIVERSITEIT ANTWERPEN (BE) | 2012-11-15 | — | — | WO | disclosed |
| US-20120214201-A1 | PROBE INCORPORATION MEDIATED BY ENZYMES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120129159-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELING USING LIPOIC ACID LIGASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-05-24 | — | — | US | disclosed |
| WO-2012050868-A1 | HISTONE DEACETYLASE (HDAC) INHIBITORS TARGETING PROSTATE TUMORS AND METHODS OF MAKING AND USING THEREOF | GEORGIA TECH RESEARCH CORPORATION (US) | 2012-04-19 | — | — | WO | disclosed |
| US-20090149631-A1 | Methods and compositions for protein labeling using lipoic acid ligases | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-06-11 | — | — | US | disclosed |
| WO-2009064366-A2 | METHODS AND COMPOSITIONS FOR PROTEIN LABELING USING LIPOIC ACID LIGASES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129159-A1 | METHODS AND COMPOSITIONS FOR PROTEIN LABELING USING LIPOIC ACID LIGASES | LARS1, ACSL5, RARS1 | TSHR 4037/4885LMNA 1218/4885NFKB1 539/4885 |
| US-20230120211-A1 | HDAC Degrader | HDAC1, HDAC11, HDAC3 | TSHR 3130/4885LMNA 2619/4885NFKB1 1284/4885 |
| US-20230099200-A1 | RADIOLABELED PEPTIDES FOR NON-INVASIVE DIAGNOSIS AND TREATMENT OF CXCR4 EXPRESSING TUMORS | CXCR4, ACKR3, CXCL12 | TSHR 550/4885LMNA 4333/4885NFKB1 1474/4885 |
| US-20090149631-A1 | Methods and compositions for protein labeling using lipoic acid ligases | HLCS, ACSL5, ACSL1 | TSHR 4081/4885LMNA 530/4885NFKB1 846/4885 |
| US-20240327418-A1 | MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR | HDAC3, HDAC1, HDAC11 | TSHR 2469/4885LMNA 867/4885NFKB1 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.